JNJ

Rating neutralAI MemoPost-earnings T+3

Johnson Johnson

As of 2026-10-16/Post-earnings T+3/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-16 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

December 8 Enterprise Business Review • 2026-12-08

Base target: $263 / p=1% prob

Biggest risk

MedTech growth of 2.5%, STELARA's roughly 690-basis-point drag on Innovative Medicine growth, adjusted EPS down 7.5% year over year, and talc-related GAAP charges weaken the quality of the beat. Post-print target cuts included RBC $290 to $280 and Wells Fargo $282 to $275; DA Davidson raised its target from $250 to $270, so revisions were mixed rather than uniformly positive. [#SEC-8K-2026-10-13] Company Q3 release Benzinga revisions MarketScreener revisions

Invalidation

Break below $225 or thesis failure.

What would change my mind?

The reported sales and adjusted-EPS beats, upward revision to July 29 guidance, 7.9% Innovative Medicine operational growth and new product authorizations support a recovery if MedTech improves. The deterministic prior is positive with a meaningful thesis-change score, but the post-print evidence does not justify an unqualified upgrade. [#SEC-8K-2026-10-13] Company Q3 release

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-16

Base target

$263

p=1%

Bull target

$285

p=0%

Bear target

$225

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q3 beat and higher guidance confront a weak MedTech reaction
New medicines and OTTAVA uptake must offset STELARA erosion
The reported sales and adjusted-EPS beats, upward revision to July 29 guidance, 7.9% Innovative Medicine operational growth and new product authorizations support a recovery if MedTech improves.

BearKey bullets

MedTech's 2.5% Q3 operational growth and reported medical-device shortfall versus expectations challenge the growth narrative.
[#SEC-8K-2026-10-13] Market reaction
STELARA biosimilar erosion, softer SIMPONI/REMICADE and other mature-product sales require sustained replacement growth.

WatchKey bullets

December 8 Enterprise Business Review

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Post-earnings T+3

Base case: $263 (p=1%)

Target spread vs base: +8% / -14%

Scenario probabilities

Bull Target: $285 (p=0%)Base Target: $263 (p=1%)Bear Target: $225 (p=0%)

Commentary

Mixed post-earnings tone: JNJ fell 5.7% on October 13 despite reported beats and a modest guidance lift, then gained 1.6% on October 14; the October 15 anchor was $253.28. Several post-print price targets were cut, although at least one was raised. The October 15 close remained below the pre-print level, so the initial negative reaction had not fully reversed. No reliable social, options-skew, short-interest or employee-sentiment measures were supplied; the zero placeholders above mean unavailable, not neutral readings. Market reaction Benzinga revisions October 15 close

As of 2026-10-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q3 beat and higher guidance confront a weak MedTech reaction
New medicines and OTTAVA uptake must offset STELARA erosion

Scenarios

Bull Target (Scenario probability)

$285 / p=0% prob

Base Target (Scenario probability)

$263 / p=1% prob

Bear Target (Scenario probability)

$225 / p=0% prob

Analysis 2026-10-16 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-08
December 8 Enterprise Business Review
The company announced a December 8 review. Investors need a quantified bridge from current Innovative Medicine strength and 2.5% MedTech operational growth to management's decade-end double-digit-growth ambition, including Orthopaedics separation assumptions. The event date is confirmed; specific new targets are not. [#8-K-2026-04-14] Company Q1 release Company Q3 release
Prob 65.00% • Move 5.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Q3 beat and higher guidance confront a weak MedTech reaction
2026-10-30
Q3 sales were $25.399B and adjusted EPS $2.59, above reported consensus of $25.25B and $2.53. JNJ raised its 2026 reported-sales midpoint to $101.2B and adjusted-EPS midpoint to $11.10 versus its July 29 outlook. Yet MedTech grew only 2.5% operationally and shares fell 5.7% on October 13; whether the selloff stabilizes is the near-term test. [#SEC-8K-2026-10-13] Company Q3 release Consensus and revisions Market reaction
Prob 60% • Move 3% • Priced-in 65%

Long-term Catalysts

Months to a year

New medicines and OTTAVA uptake must offset STELARA erosion
2027-03-31
Q3 Innovative Medicine operational sales rose 7.9%, led by TREMFYA, oncology products, SPRAVATO and CAPLYTA, while STELARA reduced segment growth by about 690 basis points. OTTAVA received U.S. market authorization, but authorization is not commercial uptake. Execution across these franchises, rather than the announced but still conditional Sail in vivo CAR-T collaboration, is the material longer-run test. [#SEC-8K-2026-10-13] [#REL-d45f6068-b685-482f-8fcd-677e1acc85c9] Company Q3 release Sail SEC exhibit
Prob 60% • Move 7% • Priced-in 50%

Risks

MedTech's 2.5% Q3 operational growth and reported medical-device shortfall versus expectations challenge the growth narrative. [#SEC-8K-2026-10-13] Market reaction
STELARA biosimilar erosion, softer SIMPONI/REMICADE and other mature-product sales require sustained replacement growth. Company Q3 release
Talc litigation remains material: Q3 reported EPS was $0.09 after a special charge tied partly to a proposed resolution. A separate JNJ filing says it retained talc-related liabilities and agreed to indemnify Kenvue for U.S. and Canadian litigation costs; the relationship record does not establish a guarantee or quantify current exposure. [#SEC-8K-2026-10-13] [#REL-4e39b5f7-7661-4ff7-8079-48247ded3ee6] JNJ SEC exhibit
The announced Orthopaedics separation and Sail collaboration carry execution uncertainty; neither should be modeled as a completed incremental earnings stream from the relationship packet.

Peers

Symbol	Summary
ABBV	Direct branded-immunology comparator for judging whether JNJ's newer medicines can replace STELARA erosion; not evidence of a specific commercial relationship.
MRK	Large-cap oncology and specialty-pharma comparator; useful for testing JNJ's diversification premium, not a direct MedTech peer.
AZN	Global innovative-medicines comparator across oncology and specialty indications; less comparable to JNJ's MedTech and talc exposures.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-16

Loading AI feed…

Symbol

Summary

ABBV

Direct branded-immunology comparator for judging whether JNJ's newer medicines can replace STELARA erosion; not evidence of a specific commercial relationship.

MRK

Large-cap oncology and specialty-pharma comparator; useful for testing JNJ's diversification premium, not a direct MedTech peer.

AZN

Global innovative-medicines comparator across oncology and specialty indications; less comparable to JNJ's MedTech and talc exposures.